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Résumé en
anglais
Triple therapy using boceprevir or telaprevir remains the reference treatment for
genotype 1 chronic hepatitis C in countries where new interferon‐free regimens have
not yet become available. Antiviral treatment is highly required in cirrhotic patients,
but they represent a difficult‐to‐treat population. We aimed to develop a simple
algorithm for the prediction of sustained viral response (SVR) in cirrhotic patients
treated with triple therapy. A total of 484 cirrhotic patients from the ANRS CO20
CUPIC cohort treated with triple therapy were randomly distributed into derivation
and validation sets. A total of 52.1% of patients achieved SVR. In the derivation set, a
D0 score for the prediction of SVR before treatment initiation included the following
independent predictors collected at day 0: prior treatment response, gamma‐GT,
platelets, telaprevir treatment, viral load. To refine the prediction at the early phase
of the treatment, a W4 score included as additional parameter the viral load collected
at week 4. The D0 and W4 scores were combined in the CUPIC algorithm defining
three subgroups: ‘no treatment initiation or early stop at week 4’, ‘undetermined’ and
‘SVR highly probable’. In the validation set, the rates of SVR in these three
subgroups were, respectively, 11.1%, 50.0% and 82.2% (P < 0.001). By replacing the
variable ‘prior treatment response’ with ‘IL28B genotype’, another algorithm was
derived for treatment‐naïve patients with similar results. The CUPIC algorithm is an
easy‐to‐use tool that helps physicians weigh their decision between immediately
treating cirrhotic patients using boceprevir/telaprevir triple therapy or waiting for
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